IL280315B2 - Methods for treating and preventing Alzheimer's disease - Google Patents
Methods for treating and preventing Alzheimer's diseaseInfo
- Publication number
- IL280315B2 IL280315B2 IL280315A IL28031521A IL280315B2 IL 280315 B2 IL280315 B2 IL 280315B2 IL 280315 A IL280315 A IL 280315A IL 28031521 A IL28031521 A IL 28031521A IL 280315 B2 IL280315 B2 IL 280315B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- months
- subject
- disease
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL280315A IL280315A (en) | 2021-03-25 |
| IL280315B1 IL280315B1 (en) | 2024-02-01 |
| IL280315B2 true IL280315B2 (en) | 2024-06-01 |
Family
ID=67551415
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280315A IL280315B2 (en) | 2018-07-24 | 2019-07-23 | Methods for treating and preventing Alzheimer's disease |
| IL310132A IL310132B1 (en) | 2018-07-24 | 2024-01-14 | Methods for treating and preventing Alzheimer's disease |
| IL323583A IL323583A (en) | 2018-07-24 | 2025-09-25 | Methods for treating and preventing Alzheimer's disease |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310132A IL310132B1 (en) | 2018-07-24 | 2024-01-14 | Methods for treating and preventing Alzheimer's disease |
| IL323583A IL323583A (en) | 2018-07-24 | 2025-09-25 | Methods for treating and preventing Alzheimer's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (enExample) |
| EP (1) | EP3826674A2 (enExample) |
| JP (2) | JP7541505B2 (enExample) |
| KR (1) | KR20210039402A (enExample) |
| CN (2) | CN112805031A (enExample) |
| AU (1) | AU2019309938A1 (enExample) |
| BR (1) | BR112021001272A2 (enExample) |
| CA (1) | CA3107370A1 (enExample) |
| IL (3) | IL280315B2 (enExample) |
| MX (1) | MX2021000778A (enExample) |
| PH (1) | PH12021500006A1 (enExample) |
| TW (1) | TW202019471A (enExample) |
| WO (1) | WO2020023530A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| PH12022552172A1 (en) * | 2020-03-20 | 2023-12-11 | Eisai R&D Man Co Ltd | High concentration anti-aã protofibril antibody formulations and methods of use thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| US20250051427A1 (en) * | 2021-12-17 | 2025-02-13 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| KR20240142535A (ko) * | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016087944A2 (en) * | 2014-12-02 | 2016-06-09 | Biogen International Neuroscience Gmbh | Method for treating alzheimer's disease |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| WO2017127764A1 (en) * | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| WO2017194789A1 (en) * | 2016-05-13 | 2017-11-16 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| WO2018005282A1 (en) * | 2016-07-01 | 2018-01-04 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| WO2018081460A1 (en) * | 2016-10-27 | 2018-05-03 | Eisai R&D Management Co., Ltd. | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| EP2538982A4 (en) * | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | PET MONITORING OF IMMUNOTHERAPY TARGETED ON A-BETA |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| SI3166970T1 (sl) | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
-
2019
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt unknown
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 AU AU2019309938A patent/AU2019309938A1/en active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-01-14 IL IL310132A patent/IL310132B1/en unknown
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| WO2016087944A2 (en) * | 2014-12-02 | 2016-06-09 | Biogen International Neuroscience Gmbh | Method for treating alzheimer's disease |
| WO2017127764A1 (en) * | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| WO2017194789A1 (en) * | 2016-05-13 | 2017-11-16 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| WO2018005282A1 (en) * | 2016-07-01 | 2018-01-04 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| WO2018081460A1 (en) * | 2016-10-27 | 2018-05-03 | Eisai R&D Management Co., Ltd. | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
Non-Patent Citations (1)
| Title |
|---|
| VERONIKA LOGOVINSKY ET AL,, SAFETY AND TOLERABILITY OF BAN2401 - A CLINICAL STUDY IN ALZHEIMER'S DISEASE WITH A PROTOFIBRIL SELECTIVE A[BETA] ANTIBODY, 6 April 2016 (2016-04-06) * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019309938A1 (en) | 2021-03-11 |
| IL310132A (en) | 2024-03-01 |
| KR20210039402A (ko) | 2021-04-09 |
| JP2024112859A (ja) | 2024-08-21 |
| IL310132B1 (en) | 2025-11-01 |
| CA3107370A1 (en) | 2020-01-30 |
| EP3826674A2 (en) | 2021-06-02 |
| US20210324056A1 (en) | 2021-10-21 |
| WO2020023530A2 (en) | 2020-01-30 |
| CN118924896A (zh) | 2024-11-12 |
| IL280315B1 (en) | 2024-02-01 |
| TW202019471A (zh) | 2020-06-01 |
| JP2021532126A (ja) | 2021-11-25 |
| WO2020023530A3 (en) | 2020-03-12 |
| JP7541505B2 (ja) | 2024-08-28 |
| CN112805031A (zh) | 2021-05-14 |
| MX2021000778A (es) | 2021-03-31 |
| BR112021001272A2 (pt) | 2021-04-27 |
| IL280315A (en) | 2021-03-25 |
| PH12021500006A1 (en) | 2021-09-13 |
| IL323583A (en) | 2025-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280315B2 (en) | Methods for treating and preventing Alzheimer's disease | |
| Qureshi et al. | A randomized, single ascending dose study of intravenous BIIB092 in healthy participants | |
| IL295459A (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| IL290727B1 (en) | A formulation for inhibiting the formation of 5-ht 2b agonists and methods of using the same | |
| IL262713B2 (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| IL302383A (en) | Method of safe administration of anti-tau antibody | |
| IL316169A (en) | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease | |
| JP2024525559A (ja) | アルツハイマー病治療用バイオマーカー | |
| US20240352109A1 (en) | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof | |
| JP2024547001A (ja) | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| JP2025506389A (ja) | ｐ－タウ１８１レベルを使用した治療方法 | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| IL271456A (en) | A pharmaceutical composition containing PCSK9 inhibitor for use in the treatment of hyperlipidemia | |
| TW202513583A (zh) | 使用抗Ａβ初原纖維抗體之治療方法 | |
| BR122025003268A2 (pt) | Métodos de tratamento e prevenção de doença de alzheimer | |
| AU2024286486A1 (en) | Methods of treatment using an anti-abeta protofibril antibody | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 |